J
Jianqing Li
Researcher at Bristol-Myers Squibb
Publications - 47
Citations - 745
Jianqing Li is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Prodrug & One-pot synthesis. The author has an hindex of 11, co-authored 47 publications receiving 578 citations.
Papers
More filters
Journal ArticleDOI
Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.
Mark D. Wittman,Joan M. Carboni,Zheng Yang,Francis Y.F. Lee,Melissa Antman,Ricardo M. Attar,Praveen Balimane,Chiehying Chang,Cliff Chen,Lorell Discenza,David B. Frennesson,Marco M. Gottardis,Ann Greer,Warren Hurlburt,Johnson Walter Lewis,David R. Langley,Aixin Li,Jianqing Li,Peiying Liu,Harold Mastalerz,Arvind Mathur,Krista Menard,Karishma Patel,John S. Sack,Xiaopeng Sang,Saulnier Mark G,Daniel J. Smith,Kevin Stefanski,George L. Trainor,Upender Velaparthi,Guifen Zhang,Kurt Zimmermann,Dolatrai M. Vyas +32 more
TL;DR: The biological activity, characterization, and SAR leading to 9d (BMS-754807) a small molecule IGF-1R kinase inhibitor in clinical development is described.
Patent
Substituted cycloalkyl P1' hepatitis C virus inhibitors
Jeffrey Allen Campbell,Andrea Stanley D,Andrew C. Good,Jianqing Li,Fiona McPhee,Amy Ripka,Paul Michael Scola,Yong Tu +7 more
TL;DR: In this paper, the authors present tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of hepatitis C virus infection.
Journal ArticleDOI
Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK)
Scott H. Watterson,Qingjie Liu,Myra Beaudoin Bertrand,Douglas G. Batt,Ling Li,Mark A. Pattoli,Stacey Skala,Lihong Cheng,Mary T. Obermeier,Robin Moore,Zheng Yang,Rodney Vickery,Paul A. Elzinga,Lorell Discenza,Celia D’Arienzo,Kathleen M. Gillooly,Tracy L. Taylor,Claudine Pulicicchio,Yifan Zhang,Elizabeth M. Heimrich,Kim W. McIntyre,Qian Ruan,Richard A. Westhouse,Ian M. Catlett,Naiyu Zheng,Charu Chaudhry,Jun Dai,Michael Galella,Andrew J. Tebben,Matt Pokross,Jianqing Li,Rulin Zhao,Daniel Smith,Richard Rampulla,Alban Allentoff,Michael Wallace,Arvind Mathur,Luisa Salter-Cid,John E. Macor,Percy H. Carter,Aberra Fura,James R. Burke,Joseph A. Tino +42 more
TL;DR: The evolution of the strategy to identify a covalent, irreversible inhibitor of BTK that has the intrinsic potency, selectivity, and pharmacokinetic properties necessary to provide a rapid rate of inactivation systemically following a very low dose is outlined.
Journal ArticleDOI
Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
Paul Michael Scola,Alan Xiangdong Wang,Andrew C. Good,Li-Qiang Sun,Keith D. Combrink,Jeffrey Allen Campbell,Jie Chen,Yong Tu,Ny Sin,Brian Lee Venables,Sing-Yuen Sit,Yan Chen,Anthony J. Cocuzza,Bilder Donna M,Stanley D'andrea,Barbara Zheng,Piyasena Hewawasam,Min Ding,Jan Willem Thuring,Jianqing Li,Dennis Hernandez,Fei Yu,Paul Falk,Guangzhi Zhai,Amy K. Sheaffer,Chaoqun Chen,Min S. Lee,Diana Barry,Jay O. Knipe,Wenying Li,Yong-Hae Han,Susan Jenkins,Christoph Gesenberg,Qi Gao,Michael Sinz,Kenneth S. Santone,Tatyana Zvyaga,Ramkumar Rajamani,Herbert E. Klei,Richard J. Colonno,Dennis M. Grasela,Eric Hughes,Caly Chien,Stephen P. Adams,Paul Levesque,Danshi Li,Jialong Zhu,Nicholas A. Meanwell,Fiona McPhee +48 more
TL;DR: A methoxy moiety at the C6 position of this isoquinoline ring system proved to be optimal with respect to potency and PK, thus providing the clinical compound 35, which demonstrated antiviral activity in HCV-infected patients.
Journal ArticleDOI
AlMe3-Promoted Formation of Amides from Acids and Amines
Jianqing Li,Krishnananthan Subramaniam,Daniel Smith,Jennifer X. Qiao,Jie Jack Li,Jingfang Qian-Cutrone,John F. Kadow,Gregory D. Vite,Bang-Chi Chen +8 more
TL;DR: A wide range of amines and acids including less nucleophilic amines, bulkyAmines, unprotected secondary amino acids, and acids with poor solubility were coupled smoothly to give the desired products in 55-98% yields.